Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin

Background: Carfilzomib is a first-line proteasome inhibitor indicated for relapsed/refractory multiple myeloma (MM), with its clinical use being hampered by cardiotoxic phenomena. We have previously established a translational model of carfilzomib cardiotoxicity in young adult mice, in which metfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Efentakis, Panagiotis, Psarakou, Garyfalia, Varela, Aimilia, Papanagnou, Eleni Dimitra, Chatzistefanou, Michail, Nikolaou, Panagiota-Efstathia, Davos, Costantinos H., Gavriatopoulou, Maria, Trougakos, Ioannis P., Dimopoulos, Meletios Athanasios, Andreadou, Ioanna, Terpos, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537073/
https://www.ncbi.nlm.nih.gov/pubmed/34681615
http://dx.doi.org/10.3390/ijms222010956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537073/
https://www.ncbi.nlm.nih.gov/pubmed/34681615
http://dx.doi.org/10.3390/ijms222010956

Ejemplares similares